Cited by 237Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchPrion Diseases and Protein Misfolding

Soluble Aβ Seeds Are Potent Inducers of Cerebral β-Amyloid Deposition

Open access
Langer, Franziska, Eisele, Yvonne S., Fritschi, Sarah K., Staufenbiel, Matthias, Walker, Lary C., Jucker, Mathias·2011·The Journal of Neuroscience

Abstract

Cerebral β-amyloidosis and associated pathologies can be exogenously induced by the intracerebral injection of small amounts of pathogenic Aβ-containing brain extract into young β-amyloid precursor protein (APP) transgenic mice. The probable β-amyloid-inducing factor in the brain extract has been identified as a species of aggregated Aβ that is generated in its most effective conformation or composition in vivo. Here we report that Aβ in the brain extract is more proteinase K (PK) resistant than is synthetic fibrillar Aβ, and that this PK-resistant fraction of the brain extract retains the capacity to induce β-amyloid deposition upon intracerebral injection in young, pre-depositing APP23 transgenic mice. After ultracentrifugation of the brain extract, <0.05% of the Aβ remained in the supernatant fraction, and these soluble Aβ species were largely PK sensitive. However, upon intracerebral injection, this soluble fraction accounted for up to 30% of the β-amyloid induction observed with the unfractionated extract. Fragmentation of the Aβ seeds by extended sonication increased the seeding capacity of the brain extract. In summary, these results suggest that multiple Aβ assemblies, with various PK sensitivities, are capable of inducing β-amyloid aggregation in vivo. The finding that small and soluble Aβ seeds are potent inducers of cerebral β-amyloidosis raises the possibility that such seeds may mediate the spread of β-amyloidosis in the brain. If they can be identified in vivo, soluble Aβ seeds in bodily fluids also could serve as early biomarkers for cerebral β-amyloidogenesis and eventually Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.3088-11.2011

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Langer, F., Eisele, Y. S., Fritschi, S. K., Staufenbiel, M., Walker, L. C., & Jucker, M.
Affiliations
  • Hertie Institute for Clinical Brain Research (DE)
  • German Center for Neurodegenerative Diseases (DE)
  • Novartis (Switzerland) (CH)
  • Emory University (US)
Venue
The Journal of Neuroscience
Published
2011-10-12
Volume
31
Issue
41
Pages
14488-14495
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W1991462232
Cited by
237
References
49
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 29 · 2020: 12 · 2019: 15 · 2018: 19 · 2017: 16 · 2016: 24 · 2015: 20 · 2014: 29 · 2013: 19 · 2012: 14
FWCI
14.84
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, public-domain)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DZNE Pub (publishedVersion)
Funders
  • Bundesministerium für Bildung und Forschung (01GI0705)
  • National Institutes of Health (RR‐00165)
  • National Center for Research Resources (P51RR000165)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
Keywords
amyloid-beta aggregation, proteinase K resistance, APP23 transgenic mice, intracerebral injection, sonication, Alzheimer's disease, biomarkers
MeSH terms
Animals, Brain, Cerebral Cortex, Enzyme-Linked Immunosorbent Assay, Female, Male, Mice, Inbred C57BL, Mice, Transgenic, Peptide Fragments, Sonication, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Endopeptidase K, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review